Skip to content

Comparing The Effects Of A Low Fat Diet Versus A Ketogenic Diet On The Motor And Non-Motor Symptoms Of Parkinson's Disease: A Randomized Controlled Trial

Comparing The Effects Of A Low Fat Diet Versus A Ketogenic Diet On The Motor And Non-Motor Symptoms Of Parkinson's Disease: A Randomized Controlled Trial

Status
Completed
Phases
Unknown
Study type
Interventional
Source
ANZCTR
Registry ID
ACTRN12617000027314
Enrollment
47
Registered
2017-01-09
Start date
2017-04-29
Completion date
2017-06-07
Last updated
2021-07-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

Parkinson’s disease may result from mitochondrial dysfunction and chronic cell energy failure (1,2). If so, a high fat, low carbohydrate “ketogenic” diet may alleviate this chronic energy failure as ketones compensate for deteriorating brain glucose metabolism (3,4), bypass deficient Complex I activity (5,6), and provide more ATP per unit oxygen than glucose (7). Previous studies have shown that physiological ketosis is beneficial in epilepsy (8) and Alzheimer’s disease (9,10). To date, one study has examined the ketogenic diet in Parkinson’s (11); it lacked a control arm. Objectives: In mid-2017, the Waikato Hospital neurology department will run a randomized controlled study with two objectives - first, to show it is feasible to institute a ketogenic diet in patients with Parkinson’s, second, to compare the effects of a low fat diet versus a ketogenic diet on motor and non-motor symptoms of Parkinson’s. Methods: Randomized controlled study over ten weeks. Baseline assessments in week 1 and 2. In week 3, participants randomized to either low fat or ketogenic diet followed by blinded clinical assessment at end of week 6. In week 7, all participants go on superior or current diet followed by blinded clinical assessment at end of week 10. (1) Bose and Beal. 2016. Mitochondrial dysfunction in Parkinson’s disease. Journal of Neurochemistry 139(Suppl 1), 216-231. (2) Perier and Vila. 2012. Mitochondrial biology and Parkinson’s Disease. Cold Spring Harbor Perspectives in Medicine 4:a009332, 1-19. (3) Roy et al. 2012. The ketogenic diet increases brain glucose and ketone uptake in aged rats: a dual tracer PET and volumetric MRI study. Brain Research 1-10. (4) Cunnane et al. 2011. Brain fuel metabolism, aging, and Alzheimer’s disease. Nutrition 27(1), 1-41. (5) Tieu et al. 2003. D-ß-Hydroxybutyrate rescues mitochondrial respiration and mitigates features of Parkinson disease. The Journal of Clinical Investigation 112(6), 892-901. (6) Gasior et al. 2006. Neuroprotective and disease-modifying effects of the ketogenic diet. Behavioural Pharmacology 17(5-6), 431-439. (7) Veech. 2004. The therapeutic implications of ketone bodies: the effects of ketone bodies in pathological conditions: ketosis, ketogenic diet, redox states, insulin resistance, and mitochondrial metabolism. Prostaglandins, Leukotrienes, and Essential Fatty Acids 70(3), 309-319. (8) Neal et al. 2008. The ketogenic diet for the treatment of childhood epilepsy: a randomized controlled trial. Lancet Neurology 7(6), 700-706. (9) Reger et al. 2004. Effects of beta-hydroxybutyrate on cognition in memory-impaired adults. Neurobiology of Aging 25, 311-314. (10) Henderson et al. 2009. Study of theketogenic agent AC-1202 in mild to moderate Alzheimer's disease: a randomized, double-blind, placebo-controlled, multicenter trial. Nutrition and Metabolism 6(31), 1-25. (11) VanItallie et al. 2005. Treatment of Parkinson disease with diet-induced hyperketonemia; A feasibility study. Neurology 64, 728-730.

Interventions

This will be a randomized controlled study with 10-40 patients in each of two groups (20-80 patients total). The study will last for ten weeks, although the actual dietary intervention will only be for eight weeks. (1) Diets. Patients will be given a four-week meal plan containing information about their diet, grocery shopping lists for each week, standard meal plan recipes, optional calorie booster recipes, and a cheat diary. Two different diets will be compared. The first diet will be low f

This will be a randomized controlled study with 10-40 patients in each of two groups (20-80 patients total). The study will last for ten weeks, although the actual dietary intervention will only be for eight weeks. (1) Diets. Patients will be given a four-week meal plan containing information about their diet, grocery shopping lists for each week, standard meal plan recipes, optional calorie booster recipes, and a cheat diary. Two different diets will be compared. The first diet will be low fat (1758 calories, 42 g fat, 75 g protein, 246 g net carbohydrate per day); by weight, the percentages will be 11% fat versus 62% net carbohydrate. The second diet will be high fat ketogenic (1758 calories, 152 g fat, 75 g protein, 16 g net carbohydrate per day - in other words, a 1.5:1 modified ketogenic diet); by weight, the percentages will be 60% fat versus 6% net carbohydrate. Notably, calorie and protein intake per day will be the same in both diets. The 1758 calories per day and macronutrient ratios given above will be the baseline diet that all participants will be expected to be able to consume. However, some participants will clearly require a higher caloric intake than this. We will provide simple recipes that substantially increase caloric intake but minimally affect protein intake for each group. For the low fat diet several low fat, high net carbohydrate supplemental options (such as fruit shakes) will be provided to the participants. For the ketogenic diet several high fat, low net carbohydrate supplemental options (such as fat shakes) will be provided to the participants. These options will allow for more calories to be consumed while maintaining the relevant fat to net carbohydrate ratio, without significantly increasing protein consumption. We will not ask the patient to maintain a detailed food diary as proof of their sticking to the diet, as previous studies have shown these to be burdensome from the patient perspective. However, we will prescribe a “cheat” diary to each patient such that if they do deviate from the meal plan, they write down the details of the food they ate that was not part of the meal plan. Dietary education and counselling will be provided throughout the study to assist patients with the practical aspects of their diet. We will endeavour to represent both diets as potentially providing health benefits. (2) Assessments. There will be one screening visit one month before the study starts for the following: (1) 0-60 minutes - Lead investigator presentation including explanation of Participant Information Sheet and signing of Consent Form. (2) 60-90 minutes - Parkinson’s nurse assessment on demographics, home situation, comorbidities, Parkinson’s diagnosis, Montreal Cognitive Assessment (MoCA) score, constipation including Bowel Function Index (BFI) score, and medications/medication allergies. (3) 90-150 minutes - Nutrition specialist assessment regarding meal preparation abilities, food preferences/food allergies, and physical status. Information required to calculate body mass index and recommended daily calorie intake will be gathered at the screening visit, but these variables will be calculated after the visit. There will be four clinical visits at Weeks 1, 2, 6, and 10 for the following: (1) 0-15 minutes - Document weight and body mass index, lying and standing blood pressure, and explain and record glucose/ketone monitor. (2) 15-30 minutes - Movement Disorder Society Unified Parkinson’s Disease Rating Scale (MDS-UPDRS) questionnaire. (3) 30-60 minutes - MDS-UPDRS blinded neurologist assessment (non-motor aspects of daily living, motor aspects of daily living, motor examination, motor complications). (4) 60-75 minutes - Bloods (CBC, EUC, lipids, uric acid, CRP). (3) Procedure. Months Before Ads in local and nation-wide Parkinson’s newsletters. Presentations to enhance awareness of study. Month Before Screening visit. Week 1 First clinical visit. Hand out and explain how to use glucose/ketone monitor. Week 2 Second clinical visit. Randomize and hand out meal plans, including cheat diaries. Week 3 Participants commence individual meal plans. Week 4 Continue. Week 5 Continue. Week 6 Third clinical visit. Immediately after the visits are completed, MDS-UPDRS scores will be analyzed to see if one meal plan is superior (participants on one meal plan have significantly improved scores compared to their aggregate baseline scores, or participants on the other meal plan have significantly worse scores compared to their aggregate baseline scores). - If one meal plan is superior, all participants go on the superior meal plan. - Otherwise, all participants stay on their current meal plan. Week 7 Participants commence superior meal plan, or stay on current meal plan. Week 8 Continue. Week 9 Continue. Week 10 Fourth clinical visit. Month After Results relayed to group. *Patients will have 24-hour access to a neurologist and a Parkinson’s nurse throughout the study. *Patients will also be contacted by phone or email every week to see how they are going.

Sponsors

Waikato Hospital
Lead SponsorHospital

Study design

Allocation
Randomised controlled trial
Primary purpose
Treatment
Masking
Blinded (masking used) (Outcomes Assessor)

Eligibility

Sex/Gender
All
Age
40 Years to 75 Years
Healthy volunteers
No

Inclusion criteria

Age 40-75 years. Body mass index >18.5. Montreal cognitive assessment (MoCA) >20. Parkinson’s diagnosis fulfilling UK Brain Bank criteria. Sufficient motivation and ability to follow either meal plan.

Exclusion criteria

Unable to provide informed consent or speak and understand English. A substance abuse, mental health, or medical condition that in the opinion of the investigators would make it difficult for the patient to take part in the study. Parkinson’s Disease extremely mild or extremely severe (Hoehn and Yahr Stages 0 and 5). Current use of weight-loss medications.

Outcome results

None listed

Source: ANZCTR · Data processed: Feb 4, 2026